Media headlines about GlycoMimetics (NASDAQ:GLYC) have been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. GlycoMimetics earned a media sentiment score of 0.04 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 46.4587578272056 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:
- GlycoMimetics (NASDAQ:GLYC) – Important Factors to Analyse A Good Investment (nasdaqjournal.com)
- The Asia Pacific Fund, Inc. (APB) Reaches $14.35 Formed H&S; Glycomimetics Has 2.5 Sentiment (mtastar.com)
- Lindblad Expeditions Holdings, Inc. (LIND) EPS Estimated At $0.03; Glycomimetics (GLYC) Shorts Up By 2.07% (mtastar.com)
- GlycoMimetics (NASDAQ:GLYC) – Active Stock Evaluation (nasdaqjournal.com)
- Healthcare Stock in Focus: GlycoMimetics, Inc. (GLYC) (stocksgeeks.com)
GLYC stock opened at $17.21 on Tuesday. The firm has a market cap of $727.10, a PE ratio of -15.23 and a beta of 3.43. GlycoMimetics has a twelve month low of $3.82 and a twelve month high of $26.05.
A number of equities research analysts have recently weighed in on GLYC shares. ValuEngine upgraded GlycoMimetics from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Roth Capital set a $35.00 target price on GlycoMimetics and gave the stock a “buy” rating in a research report on Thursday, February 8th. BidaskClub upgraded GlycoMimetics from a “hold” rating to a “buy” rating in a research report on Thursday, January 11th. Stifel Nicolaus boosted their target price on GlycoMimetics from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, March 7th. Finally, Jefferies Group restated a “buy” rating and set a $21.00 target price on shares of GlycoMimetics in a research report on Wednesday, December 20th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $23.00.
TRADEMARK VIOLATION NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect GlycoMimetics (GLYC) Stock Price” was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.chaffeybreeze.com/2018/04/17/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-glycomimetics-glyc-stock-price.html.
GlycoMimetics Company Profile
GlycoMimetics, Inc, a clinical stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. Its advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and has evaluated in a Phase 3 clinical trial, conducted by its strategic collaboration with Pfizer Inc The company's drug candidate, GMI-1271, an E-selectin antagonist, is evaluated in a Phase 1/2 clinical trial as a potential treatment for acute myeloid leukemia and is in a Phase 1 clinical trial for the treatment of multiple myeloma.
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.